Profile data is unavailable for this security.
About the company
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
- Revenue in CAD (TTM)0.00
- Net income in CAD-8.14m
- Incorporated2006
- Employees11.00
- LocationBriacell Therapeutics CorpSuite 300 - Bellevue Centre235 -15th StreetWEST VANCOUVER V7T 2X1CanadaCAN
- Phone+1 (604) 921-1810
- Fax+1 (604) 921-1898
- Websitehttps://briacell.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Resverlogix Corp | 0.00 | -14.57m | 17.98m | 18.00 | -- | -- | -- | -- | -0.0559 | -0.0559 | 0.00 | -0.3805 | 0.00 | -- | -- | 0.00 | -138.80 | -- | -- | -- | -- | -- | -- | -- | 0.0459 | -0.8227 | -- | -- | -- | -- | -363.74 | -- | -- | -- |
| Sirona Biochem Corp | -12.09k | -2.31m | 18.12m | -- | -- | -- | -- | -- | -0.0091 | -0.0091 | -0.00005 | -0.012 | -0.0114 | -- | 0.5203 | -- | -218.11 | -173.09 | -- | -383.49 | -- | -- | -- | -1,405.28 | -- | -8.11 | -- | -- | -94.82 | -51.37 | 28.52 | -- | -- | -- |
| COSCIENS Biopharma Inc | 6.13m | -17.10m | 20.55m | 21.00 | -- | 0.4783 | -- | 3.35 | -12.69 | -12.69 | 3.62 | 11.62 | 0.0936 | 1.74 | 6.35 | -- | -26.11 | -26.24 | -30.53 | -30.34 | 39.42 | 83.68 | -278.95 | -300.31 | 3.05 | -- | 0.0604 | -- | -20.25 | -30.06 | 27.17 | -- | 16.12 | -- |
| Briacell Therapeutics Corp | 0.00 | -8.14m | 27.02m | 11.00 | -- | -- | -- | -- | -0.531 | -0.531 | 0.00 | -0.5065 | 0.00 | -- | -- | 0.00 | -33.97 | -59.37 | -43.50 | -63.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.35 | -- | -- | -- |
| Thiogenesis Therapeutics Corp | 0.00 | -4.49m | 31.85m | -- | -- | 6.70 | -- | -- | -0.1092 | -0.1092 | 0.00 | 0.1045 | 0.00 | -- | -- | -- | -91.94 | -- | -98.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Nurexone Biologic Inc | 0.00 | -5.62m | 37.82m | 8.00 | -- | 10.77 | -- | -- | -0.1082 | -0.1082 | 0.00 | 0.052 | 0.00 | -- | -- | -- | -183.97 | -213.78 | -235.34 | -596.97 | -- | -- | -- | -- | -- | -187.27 | 0.0096 | -- | -- | -- | 55.45 | -- | -- | -- |
